IPSEN (OTCMKTS:IPSEY) Reaches New 52-Week High - Time to Buy?

Key Points

• IPSEN's stock price reached a new 52-week high of $35.08, with a recent trading volume of 233 shares.
• The company is actively involved in the biopharmaceutical sector, focusing on areas such as oncology, neuroscience, and rare diseases.
• IPSEN's product pipeline includes multiple drugs in clinical trials, including Cabometyx and Dysport, targeting various medical conditions.

IPSEN (OTCMKTS:IPSEY - Get Free Report)'s share price reached a new 52-week high during trading on Friday . The company traded as high as $35.08 and last traded at $35.08, with a volume of 233 shares. The stock had previously closed at $34.85.

IPSEN Trading Down 0.8%

The business has a 50-day moving average price of $32.71 and a 200-day moving average price of $30.32.

About IPSEN

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.